Prime Medicine, Inc.

PRME

Precision medicineBiotech & pharmaceuticals

$3.25vs prev close▼-0.14(-4.13%)

$2.6752W Range$6.94

14% from low

+0.30 (+10.17%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.19%

1M +0.05%p

Holding ETFs

1 ETFs

ARKG

Buy · Weight Up

ARK net-bought the stock and the price rose, increasing its portfolio weight.

Shares +55.4% · Market value +19.9% · Weight +0.05%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.07.22	BUY	ARKG	206,310	$3.09	$637.5K
26.07.21	BUY	ARKG	76,393	$3.12	$238.3K
26.07.20	BUY	ARKG	491,418	$3.05	$1.5M
26.07.17	BUY	ARKG	81,580	$3.13	$255.3K
26.07.16	BUY	ARKG	424,438	$3.22	$1.4M
26.07.15	BUY	ARKG	54,881	$3.49	$191.5K
26.07.14	BUY	ARKG	88,796	$3.47	$308.1K
26.07.13	BUY	ARKG	246,729	$3.52	$867.3K
26.07.10	BUY	ARKG	293,106	$3.78	$1.1M
26.07.09	BUY	ARKG	544,385	$4.23	$2.3M
26.07.07	BUY	ARKG	206,193	$3.99	$822.7K
25.09.10	BUY	ARKG	230,755	$3.89	$897.6K
25.09.09	BUY	ARKG	157,413	$4.12	$648.5K
25.07.31	BUY	ARKG	2,356,661	$3.74	$8.8M
25.04.21	SELL	ARKK	33	$1.39	$46

07.22BUY

206,310

ARKGClose$3.09Est. total$637.5K

07.21BUY

76,393

ARKGClose$3.12Est. total$238.3K

07.20BUY

491,418

ARKGClose$3.05Est. total$1.5M

07.17BUY

81,580

ARKGClose$3.13Est. total$255.3K

07.16BUY

424,438

ARKGClose$3.22Est. total$1.4M

07.15BUY

54,881

ARKGClose$3.49Est. total$191.5K

07.14BUY

88,796

ARKGClose$3.47Est. total$308.1K

07.13BUY

246,729

ARKGClose$3.52Est. total$867.3K

07.10BUY

293,106

ARKGClose$3.78Est. total$1.1M

07.09BUY

544,385

ARKGClose$4.23Est. total$2.3M

07.07BUY

206,193

ARKGClose$3.99Est. total$822.7K

09.10BUY

230,755

ARKGClose$3.89Est. total$897.6K

09.09BUY

157,413

ARKGClose$4.12Est. total$648.5K

07.31BUY

2,356,661

ARKGClose$3.74Est. total$8.8M

04.21SELL

ARKKClose$1.39Est. total$46

1 / 5

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

7,494,865

Portfolio Weight

0.19%

in ETF 1.39%

Est. Value

$23M

30D Net

+$9M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Analyst Targets

avg.

$7.30

vs Current ▲ +115.2% upside

Current$3.39

Low ~ High$4.25 ~ $11.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

BMO Capital

Outperform

$9.00

+165.49%

$3.54

Upgrade

2026-08-19

HC Wainwright & Co.

Buy

$8.00

+135.99%

$3.15

Maintain

2026-08-10

HC Wainwright & Co.

Buy

$8.00

+135.99%

$3.72

Upgrade

2026-06-29

Oppenheimer

Outperform

$11.00

+224.48%

$3.73

Upgrade

2026-03-12

LifeSci Capital

Outperform

$6.00

+76.99%

$3.69

Upgrade

2025-12-23

1 / 4

Avg Target

$7.30

vs Current ▲ +115.2% upside

Buy

13 analysts

Strong Buy 1Buy 9Hold 3

Low $4.25

Current $3.39

High $11.00

Firm	Position	Target	Upside	Close	Action	Date
BMO Capital	Outperform	$9.00	+165.49%	$3.54	Upgrade	26.08.19
HC Wainwright & Co.	Buy	$8.00	+135.99%	$3.15	Maintain	26.08.10
HC Wainwright & Co.	Buy	$8.00	+135.99%	$3.72	Upgrade	26.06.29
Oppenheimer	Outperform	$11.00	+224.48%	$3.73	Upgrade	26.03.12
LifeSci Capital	Outperform	$6.00	+76.99%	$3.69	Upgrade	25.12.23

1 / 4

Price Information

Previous Close$3.39

Open$3.28

Day Range$3.24 - $3.48

52-Week Range$2.67 - $6.94

1-Year Change-3.69%

Trading Volume

Volume3,583,294

Avg Volume (3mo)3,375,606

Valuation

Market Cap614.9M

Book Value$0.23

Shares Outstanding181,376,856

Financials

Revenue (TTM)4.1M

Net Income-187,892,000

EPS$-1.05

EBITDA-189,122,000

Profitability

P/E Ratio-

P/B Ratio15.07

Return on Equity (ROE)-373.29%

Return on Assets (ROA)-46.52%

Profit Margin0.00%

EV/EBITDA-3.28

Beta2.31

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)64.36

Company Overview

Prime Medicine, Inc. is a biotechnology company focused on delivering genetic therapies for a wide range of diseases using its proprietary Prime Editing technology. This innovative platform allows for precise DNA editing without causing double-stranded breaks, enabling targeted genetic corrections. The company is actively developing treatments for genetic diseases and certain cancers through internal research and collaborations.

P/B

15.07

High valuation

ROE

-373.3%

Persistent loss

Beta

2.31

Extreme volatility

RSI(14)

64.4

Neutral zone

AI-generated summary. Not investment advice.

Prime Medicine, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks